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Hepatic lipogenesis is nutritionally regulated (i.e.,
downregulated during fasting and upregulated dur-
ing the postprandial state) as an adaptation to the
nutritional environment. While alterations in the
expression level of the transcription factor SREBP-
1c are known to be critical for nutritionally regu-
lated lipogenesis, upstream mechanisms governing
Srebf1 expression remain unclear. Here, we show
that the fasting-induced transcription factor KLF15,
a key regulator of gluconeogenesis, forms a complex
with LXR/RXR, specifically on the Srebf1 promoter.
This complex recruits the corepressor RIP140
instead of the coactivator SRC1, resulting in reduced
Srebf1 and thus downstream lipogenic enzyme
expression during the early and euglycemic period
of fasting prior to hypoglycemia and PKA activation.
Through this mechanism, KLF15 overexpression
specifically ameliorates hypertriglyceridemia without
affecting LXR-mediated cholesterol metabolism.
These findings reveal a key molecular link between
glucose and lipid metabolism and have therapeutic
implications for the treatment of hyperlipidemia.
INTRODUCTION
In the postprandial state, the liver takes up nutrients through
the portal vein and excess carbohydrates are converted into tri-
glycerides, whereas in a fasting state, this lipogenic pathway
shuts down. Previous studies have shown that sterol regulatory
element-binding protein-1c (SREBP-1c) plays an important role
in controlling hepatic lipogenesis (Shimano et al., 1999; Yahagi
et al., 1999, 2002), leading us to examine the mechanism of
this nutritional regulation of SREBP-1c expression.Cell R
This is an open access article undUpon fasting, mRNA expression of the Srebf1 gene is mark-
edly decreased, resulting in reduced amounts of SREBP-1c pro-
tein in liver nuclei, with corresponding decreases in the mRNAs
for SREBP-1-activated target genes such as fatty acid synthase
(gene name, Fasn), a rate-limiting enzyme for lipogenesis (Horton
et al., 1998). Previously, we and other authors have shown that
liver X receptor (LXR), a nuclear receptor family member, tran-
scriptionally regulates the Srebf1 gene expression (Repa et al.,
2000; Yoshikawa et al., 2001). It has also been shown that insu-
lin-dependent (Chen et al., 2004, 2007; Kim et al., 1998; Shimo-
mura et al., 1999; Sun et al., 2016) and insulin-independent (Haas
et al., 2012; Matsuzaka et al., 2004) upstreammechanisms regu-
late SREBP-1 levels. Overall, the precise molecular mechanism
by which LXR regulates Srebf1 gene expression under distinct
nutritional conditions remains unclear.
Here, we show through a series of experiments involving
a genome-wide screening for transcription factors that fasting-
induced Kr€uppel-like factor 15 (KLF15) interacts with LXR to
repress Srebf1 gene transcription as the primary mechanism of
this nutritional regulation. The Kr€uppel-like family of transcription
factors is a subclass of Cys2/His2 zinc-finger DNA-binding pro-
teins, and KLF15 is expressed in multiple tissues, including the
liver, white and brown adipose tissue, kidney, heart, and skeletal
muscle, with the strongest expression levels occurring in the liver
and kidney (Gray et al., 2002). The hepatic abundance of KLF15
is induced during the fasting state, and KLF15 is known to
contribute to the regulation of gluconeogenesis in the liver
(Gray et al., 2007; Teshigawara et al., 2005).
RESULTS
Identification of NuRE on the Srebf1c Promoter by
In Vivo Ad-Luc Analyses
mRNA expression of hepatic Srebf1 gene is tightly regulated by
nutritional conditions. Using in vivo reporter gene analyses with
reporter-transgenic mice, we previously showed that this nutri-
tional regulation of the Srebf1 gene occurs at the transcriptionaleports 16, 2373–2386, August 30, 2016 ª 2016 The Authors. 2373
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
level and that a 2.2-kb region of the 50-flanking sequence on the
Srebf1c promoter is sufficient for this regulation (Takeuchi et al.,
2007). Moreover, we previously established an intra-organ assay
system to directly estimate the activity of theSrebf1c promoter in
the livers of living animals using an adenovirus encoding the
Srebf1c promoter linked to a luciferase reporter gene (Takeuchi
et al., 2010). Using this in vivo Ad-luc promoter analysis
technique, we attempted to identify the nutritional regulatory
cis element on the Srebf1c promoter; luciferase reporter genes
driven by different lengths of the Srebf1c promoter (ranging
from 2,200 bp to 150 bp) were adenovirally transduced into
mouse liver, and transcriptional activity was assessed by
measuring luciferase activity with an IVIS imaging system (Fig-
ure 1A). From this experiment, the responsible element was
found to be located within 250 to 150 bp upstream of the
transcription start site. This result was confirmed by experiments
using another series of adenovirus constructs encoding different
partial sequences of the Srebf1c promoter to estimate enhancer
activity (Figure S1A).
Next, we investigated the 250- to 150-bp region in detail;
this region contains two LXR-binding elements (LXREs) (Yoshi-
kawa et al., 2001). Intriguingly, the two LXREs alone were not
sufficient for nutritional regulation, although they exhibited a
complete response to an LXR ligand (Figure 1B), suggesting
that nutritional regulation is not brought about by changes in
ligand concentration. Further scrutiny clarified that a cis element
flanking the LXRE besides the two LXREs is indispensable for
nutritional regulation (Figure 1C). This element, which we desig-
nated the nutritional regulatory element (NuRE), was subse-
quently shown to exert a suppressive effect on the Srebf1c pro-
moter in a fasting state (Figures 1D and S1B). Consistent with
this finding, an electrophoretic mobility shift assay (EMSA)
showed a fasting-specific band (Figure 1E), suggesting that
some fasting-acting transcription factor(s) in liver nuclei that
binds to NuRE may be involved in the suppression of Srebf1c
promoter activity during fasting.
Previous reports have indicated the involvement of LXR/RXR
in the regulation of Srebf1c promoter activity (Repa et al.,
2000; Yoshikawa et al., 2001), as supported by our own data
demonstrating that the simultaneous knockdown of both LXRa
and bmarkedly reduces the nutritional response of Srebf1c pro-
moter activity (Figures S1C–S1E). Based on these lines of evi-
dence and the fact that mRNA and protein expression levels as
well as DNA binding of LXRa/b were not altered by dietary ma-
nipulations (Figure 2F), we hypothesized that this unknown tran-
scription factor binding to NuRE conferred a negative regulatory
effect on LXR/RXR transcriptional activity.
TFEL Genome-wide Screen of trans-Acting Factors
for NuRE
To identify the hypothetical transcription factor(s) that binds
to NuRE and represses LXR/RXR on the Srebf1c promoter,
we screened 1,588 genome-wide transcription factor genes
included in the TFEL (Transcription Factor Expression Library;
N.Y. and Y.T., unpublished data), and assessed the suppressive
effects of individual transcription factors against the activity of
the promoter containing NuRE plus two LXREs in the presence
of cotransfected LXRa/RXRa (Figures 1F, S1F, and S1G). After2374 Cell Reports 16, 2373–2386, August 30, 2016three rounds of screening, two transcription factors (KLF15
and KLF4) were identified as candidates (Figures 1G and S1H).
KLF15 and KLF4 suppressed the promoter containing NuRE
plus two LXREs in an NuRE-dependent manner, while KLF family
members other than KLF15 and KLF4 did not (Figure 2A). In addi-
tion, EMSAs demonstrated that recombinant KLF15 and KLF4
proteins bind to the NuRE probe (Figures 2B, S2A, and S2B).
This element includes a 50-CCCCATTC-30 sequence that resem-
bles the 50-CCCCACCC-30 consensus motif of KLF family mem-
bers (Jiang et al., 2008).
These results were further supported by an in vivo mutation
analysis, which demonstrated that the mutation at the KLF-
binding site decreased the response of the native Srebf1c pro-
moter activity to dietary manipulations (Figures S2C and S2D).
The DNA sequences of this KLF-binding site as well as the two
LXREs are highly conserved among vertebrates (Figure 2C).
Fasting-Induced KLF15 Binds to NuRE
Next, we examined KLF15 and KLF4 expression levels in the
liver. Several KLFs are known to be widely expressed in various
organs involved in energy metabolism (Gray et al., 2007; Mori
et al., 2005; Teshigawara et al., 2005; Uchida et al., 2000). The
expression of KLF15 in the liver was robust and markedly
increased with fasting (Figure 2D), consistent with previous
reports (Takashima et al., 2010; Teshigawara et al., 2005). By
contrast, hepatic KLF4 expression was a thousand-fold lower.
Accordingly, the nuclear protein detected using the EMSA to
bind to NuRE during fasting was identified as KLF15 based on
the disappearance of the band when adding anti-KLF15 anti-
body (Figure 2E). Furthermore, chromatin immunoprecipitation
(ChIP) assays showed that KLF15 binding to the NuRE was
markedly increased in the fasting state compared with the re-
fed state (Figure 2F). In contrast, the elevation of KLF4 expres-
sion to the 2-fold level of the fasting condition using adenovirus
had no effects on Srebf1c transcription (Figures S2E–S2H).
Based on these data, we excluded KLF4 as a candidate for the
NuRE-binding transcription factor and focused on KLF15 in the
following studies.
Role of KLF15 in Srebf1 Regulation
To clarify the role of KLF15 in the regulation of Srebf1 gene
expression in the in vivo liver, we examined the influences of
the forced expression or the knockdown of KLF15 using adeno-
viruses. Interestingly, forced overexpression of KLF15 in re-fed
mouse livers to levels comparable to those observed in the
fasted state led to complete repression of Srebf1c promoter
activity (Figures 3A, S3A, and S3B), a decrease in mRNA and
nuclear protein levels of SREBP-1 (Figures 3B and S3C), a
decrease in the promoter activity and mRNA level of Fasn (Fig-
ures 3B and 3C), and consequently a decrease in plasma triglyc-
eride levels (Figure 3D). The suppressive effect of KLF15 on Fasn
mRNA levels was completely abolished by the enforced expres-
sion of SREBP-1c (Figure S3D), demonstrating that the effect of
KLF15 on hepatic lipogenesis is mediated via suppression of
SREBP-1c. The adenovirally transduced KLF15 also repressed
Srebf1 expression while inducing Pck1 (the gene name for
phosphoenolpyruvate carboxykinase, the rate-limiting enzyme
in gluconeogenesis) in primary hepatocytes (Figures S3E and
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Figure 1. Identification of KLF15 through In Vivo Ad-Luc Promoter Analyses and a TFEL Genome-wide Screen
(A–D) In vivo Ad-luc promoter analyses of the Srebf1c gene. Hepatic luciferase activities of mice injected with Ad-Srebf1c-Luc (n = 5–12 per group) are shown.
(A–C) Luciferase activity in the 24-hr fasted state is expressed as a percentage of that in the 16-hr re-fed state. F, fasted; R, re-fed.
(A) Various lengths of the Srebf1c promoter (top right: northern blot analysis of Srebf1 expression in liver from fasted and re-fed mice).
(B) (249 to 144) and (239 to 165) including two LXREs and the mutated LXREs (mtLXRE) attached to an SV40 promoter. LXR ligand T0901317-
administrated mice versus control mice are also shown.
(C) Various regions of the Srebf1c promoter attached to an SV40 promoter.
(D) Comparison between constructs with or without NuRE. Luciferase activity per transduced adenoviral DNA is shown.
(E) Electrophoretic mobility shift assay with radiolabeled probe for NuRE and liver nuclear extract proteins from fasted and re-fed mice.
(F) Processes of screening to identify transcription factors that bind to NuRE using TFEL (Transcription Factor Expression Library). In the first screening, all the
1,588 TFEL clones were cotransfected individually into HEK293 cells together with LXRa/RXRa expression plasmids and Srebf1c-(LXREx2+NuRE)-SV40p-Luc
reporter plasmid to evaluate suppressive effects on LXREs plus NuRE. In the second screening, TFEL clones showing non-specific suppressive effects on the
SV40 promoter were eliminated. In the third screening, the specificity of suppression was further verified.
(G) NuRE-dependent inhibition of KLF15 and KLF4 against Srebf1c promoter activity in the presence of LXRa/RXRa in HEK293 cells (n = 3 per group). Luciferase
activity is expressed as a percentage of control.
Results are presented as means ± SEM. **p < 0.01 versus control of each group. See also Figure S1.S3F). In contrast, the mRNA level of Abca1, another representa-
tive target gene of LXR, was not influenced by KLF15 overex-
pression (Figure 3B), demonstrating that this KLF15-mediated
suppression of LXR is dependent onNuRE and therefore specific
to the Srebf1c promoter.
Conversely, when we evaluated the contribution of KLF15 in
the fasting state by knockdown, promoter activity as well as the
expression of Srebf1 and, consequently, Fasn genes was mark-
edly elevated despite fasting conditions, whereas Pck1 expres-
sion was significantly decreased (Figures 3E, 3F, S3G, andS3H). The two small hairpin RNAs (shRNAs) exerted essentially
the same effects on expression levels of SREBP-1c, excluding
the possibility of off-target effects (Figures S3I–S3K). In contrast,
themRNA level ofAbca1was not affected byKLF15 knockdown,
again showing that the KLF15-mediated inhibition of LXR is spe-
cific to the Srebf1c promoter. The effect of KLF15 knockdown
was shown to be dependent on NuRE (Figure S3L).
To further check the validity of our model, we analyzed KLF15
knockout mice. KLF15 knockout mice exhibited significantly
higher activities of Srebf1c promoter at an early stage of fastingCell Reports 16, 2373–2386, August 30, 2016 2375
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Figure 2. Fasting-Induced KLF15 Binds to NuRE on the Srebf1c Promoter
(A) Inhibitory effects of KLF family members on the Srebf1c promoter in the presence of LXRa/RXRa in HEK293 cells (n = 3 per group).
(B) Electrophoreticmobility shift assay with radiolabeled probe for NuRE andGST-KLF15DBDorGST-KLF4DBD recombinant proteins (+, 100 ng; ++, 500 ng). wt,
wild-type; mt, mutant.
(C) Result of a UCSC genome browser query (http://genome.ucsc.edu/) showing conservation of the KLF-binding site in the Srebf1c promoter among vertebrate
species.
(D) qRT PCR analysis of Klf15 and Klf4mRNA copy numbers and Srebf1cmRNA levels in various tissues from fasted and re-fed mice (n = 3–4 per group). L, liver;
W, white adipose tissue; B, brown adipose tissue; SM, skeletal muscle; CM, cardiac muscle.
(E) Electrophoretic mobility shift assay using radiolabeled probe for the KLF-binding site in the Srebf1c promoter and liver nuclear extracts from fasted and re-fed
mice. KLF15-specific binding was shown using an anti-KLF15 antibody (immunoglobulin G [IgG] as a negative control). F, fasted; R, re-fed.
(F) Chromatin immunoprecipitation assay with liver nuclear extracts and anti-KLF15, anti-LXRa/b, anti-RXRa, and anti-SREBP1 antibodies along with IgG as a
negative control. PCR was conducted with primers for two LXREs plus NuRE in the Srebf1c promoter or SRE in the Fasn promoter as a control.
Results are represented as means ± SEM.
See also Figure S2.(6 hr of fasting) as assessed by luciferase reporter assay and
quantified using in vivo imaging system (Figure 3G). In accor-
dance with this, the rapid decrease of Srebf1c, Fasn mRNA,
and plasma triglycerides (TGs) as well as the rapid increase in2376 Cell Reports 16, 2373–2386, August 30, 2016Pck1 mRNA observed in wild-type mice after 6 hr of fasting
was not seen in KLF15 knockout mice (Figures 3H, 3I, S4A,
and S4B). These data were consistent with those from the
knockdown experiments.
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Figure 3. Role of KLF15 in Srebf1 Regulation
(A–D) Effects of KLF15 elevation. KLF15 were elevated to the fasting level in re-fed mouse liver using an adenovirus (Ad-KLF15).
(E and F) Effects of KLF15 knockdown. Knockdown of hepatic KLF15 was performed using adenovirus-mediated RNAi (Ad-KLF15i).
(G–J) Analyses of KLF15 knockout (KO) compared with wild-type (WT) mice.
(legend continued on next page)
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By contrast, after prolonged fasting (24 hr of fasting), the
Srebf1c promoter activities of KLF15 knockout mice were sup-
pressed to the similar levels as those of the wild-type con-
trol mice. To clarify the compensatory mechanism in KLF15
knockout mice that finally suppressed SREBP-1c to the same
low levels seen in wild-type mice under the prolonged (24-
hr) fasting condition, we examined blood profiles of KLF15
knockout mice. Consistent with a previous report (Gray et al.,
2007), KLF15 knockout mice showed significantly lower blood
glucose levels (Figure S4C), leading to the marked elevation of
plasma glucagon levels (Figure S4D). We found that this in turn
activated the hepatic protein kinase A (PKA) pathway in KLF15
knockout mice (Figures 3J and S4E–S4G), which led to the
suppression of LXR/RXR transcriptional activity (Yamamoto
et al., 2007).
Consistently, the mRNA and protein abundance of Klf15
and Srebf1 in the liver showed reciprocal changes according
to the time course of fasting or re-feeding (Figures 3K–3M).
Moreover, the reverse correlation between KLF15 and SREBP-
1 was preserved when animals were re-fed with various amounts
of food (Figure 3N).
To further verify if this suppression by KLF15 actually occurs
during the physiological time course, we checked the suppres-
sive effect of KLF15 using the Tet-on system, where the rapid in-
duction of KLF15 is driven by doxycycline (Dox) (Figures S4H–
S4K). As shown in Figures 3O–3Q (see also Figure S4K), Dox
administration quickly suppressed Srebf1c promoter activity.
From these multiple lines of evidence, we concluded that fast-
ing-induced KLF15 binds to NuRE and suppresses Srebf1c
promoter activity by inhibiting LXR/RXR and that KLF15 rapidly
controls expression levels of SREBP-1c.
Mechanism of the KLF15-LXR Interaction
To elucidate the molecular mechanism of KLF15 suppression
against LXR/RXR, the molecular interaction between KLF15
and LXR/RXR was assessed using coimmunoprecipitation ex-
periments. KLF15 and LXR/RXR were shown to form a complex
in cultured cell and in vivo liver nuclei (Figure 4A). Notably, the
LXR-RXR interaction was not influenced by KLF15 (Figure 4B).
To understand the specificity of this KLF15-LXR/RXR inter-
action, we investigated the binding of KLF family members,
including KLF15 and KLF4, to LXRa and RXRa using glutathione
S-transferase (GST) pull-down assays. Among the KLFs that
were tested (KLF1, 4, 5, 9, 10, and 15), only KLF15 and KLF4
bound to LXRa (Figure 4C). Essentially the same results were(A, E, andG) Changes in Srebf1c promoter activities. Images captured using IVIS a
re-fed (A) or fasted (E) mice are shown (n = 7–11 per group). F, fasted; R, re-fed.
(B, F, and H) qRT PCR analysis of gene expression in the livers of re-fed (B) or fast
fasting (H) (n = 5–12 per group).
(C) Changes in hepatic Fasn promoter activities (n = 7–8 per group).
(D and I) Plasma triglyceride levels of the mice injected Ad-KLF15 in the re-fed s
(J) Hepatic PKA activities in KLF15 knockout mice during fasting (n = 6–7 per gro
(K–N) Changes in hepatic klf15 and Srebf1 gene expression (K, L, and N) and nucle
re-feeding (L) and relationship with the amount of food intake (N) (n = 3 per grou
(O–Q) Quick induction of KLF15 expression in re-fed mouse liver by adenoviru
administered 1 mg/ml doxycycline (Dox) in their drinking water for 16 hr (Ad-tet-on
KLF15 (O). Hepatic Srebf1c promoter activities (P). Hepatic gene expression in r
Results are presented as means ± SEM. *p < 0.05 and **p < 0.01 versus control
2378 Cell Reports 16, 2373–2386, August 30, 2016obtained using mammalian two-hybrid experiments (Figure 4D).
RXRa showed a broader specificity for KLF5, KLF9, and KLF10,
in addition to KLF15 and KLF4. Taken together with the finding
that other KLFs such as KLF5, 9, and 10 can bind to the NuRE
sequence (Figures S2A and S2B), the specificity of KLF15 and
KLF4 on the suppression of Srebf1c promoter activity (Figure 2A)
is considered to be attributable to the specific binding of LXR
to KLF15 and KLF4. Intriguingly, KLF15 also has an affinity for
RARa, and RAR was interchangeable with LXR as a partner for
KLF15 (Figures S5A and S5B).
Next, we attempted to determine the domain of KLF15
responsible for the interaction with LXRa. KLF15 consists of
two domains: an N-terminal repression and activation domain
(RAD) and a C-terminal DNA-binding domain (DBD) composed
of three zinc-finger domains. 35S-labeled deletion derivatives
of KLF15 were subjected to a pull-down assay with GST-LXRa,
and the zinc-finger domain of KLF15 was shown to be critical
for its interaction with LXRa (Figure 4E). Supporting this finding,
a truncated KLF15 lacking the zinc-finger domain had no effect
on the inhibition of LXR/RXR activity (Figure 4F). Similarly, to
map the domain of LXRa required for this interaction, we per-
formed pull-down assays using GST fusion proteins containing
various domains of LXRa, which consists of four domains:
a ligand-independent activation function domain (A/B), a
DNA-binding domain (C), a ligand-binding domain (DE), and a
ligand-dependent transactivation function-2 domain (AF2).
These pull-down assays revealed that the C domain of LXRa
is critical for its interaction with KLF15 (Figure 4G). A compa-
rable result was observed for the RXRa-KLF15 interaction
(Figure S5C).
These results demonstrate that KLF15 and LXRa interact with
each other through the DNA-binding domain on each molecule.
The DNA-binding domains of transcription factors, including nu-
clear receptors, can also function as an interacting domain with
other proteins (Yin et al., 2002). The EMSA results (Figure S5D)
confirmed that KLF15 and LXRa/RXRa actually form a complex
on the DNA fragment containing LXRE plus NuRE, whereas the
binding of KLF15 or LXRa/RXRa to each corresponding element
was not affected by LXRa/RXRa or KLF15, respectively.
KLF15 Represses LXR by Recruiting the RIP140
Corepressor
To further explore the detailed mechanism of how KLF15
suppresses LXR/RXR, we attempted to identify additional cofac-
tor(s) that may be operative. Three corepressors (NcoR1, SMRTnd quantified luciferase activities per transduced adenoviral DNA in the livers of
ed (F) mice from each group (n = 8 per group) and KLF15 knockout mice during
tates (D), and KLF15 knockout mice during fasting (I) (n = 7–10 per group).
up).
ar proteins (M) in the various nutritional states. Time course during fasting (K) or
p).
s using the Tet-on system (Ad-tet-on-KLF15). In the re-fed state, mice were
-KLF15, n = 7–12 per group; Ad-GFP, n = 3 per group). Schema of Ad-tet-on-
e-fed mice (Q). F, fasted; R, re-fed.
of each group. See also Figures S3 and S4.
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(legend on next page)
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[NcoR2], and RIP140) can reportedly be coupled with LXRa
or b-mediated transcription (Glass et al., 1997; Hu et al., 2003;
Jakobsson et al., 2007; Yamamoto et al., 2007). To test the
possible involvement of these corepressors in the KLF15-
induced inhibition of LXR activity, mammalian two-hybrid assays
were performed. This system detects the binding of a VP16-AD-
LXRa fusion protein and GAL4-DBD-corepressor-NID (a func-
tional domain that interacts with nuclear receptors) in HEK293
cells (Figures 5A and S5E). Unlike NcoR1 and SMRT, the
hybridization between RIP140 and LXRa was enhanced by
KLF15, indicating that KLF15 promotes the recruitment of the
RIP140 corepressor to LXRa. This result was confirmed by
immunoprecipitation experiments (Figure 5B). In particular, the
amount of LXR-RIP140 complex was much more abundant in
the presence of KLF15 in wild-type mice compared with KLF15
knockout mice, although LXR and RIP140 themselves were pre-
sent at the similar levels in both models of mice (Figure S5F).
We also checked the possible involvement of a major coacti-
vator coupled with LXR, steroid receptor coactivator-1 (SRC1)
(Huuskonen et al., 2004); KLF15 specifically decreased the
recruitment of SRC1 to LXRa (Figure 5C), while KLF family mem-
bers other than KLF15 did not (Figure S5G).
Next, we examined the physiological changes in the amount of
LXR-RIP140 and LXR-SRC1 complexes during fasting and re-
feeding in an in vivo setting. When liver nuclear extracts were
immunoprecipitated with anti-LXRa/b antibody and coprecipi-
tated RIP140 and SRC1 were visualized using western blotting,
a larger amount of LXR-RIP140 complex was found in the fasting
state (Figure 5D). In contrast, SRC1 coupled with LXR was recip-
rocally decreased in the fasting state, suggesting that RIP140
recruitment assisted by KLF15 competes with SRC1 binding to
LXR and thus inhibits transcriptional activity. A ChIP assay using
RIP140 and SRC1 antibody also exhibited reciprocal patterns
between RIP140 and SRC1 (Figure 5E). When we tested if
RIP140 and SRC1 compete against each other when binding
to LXRa using a GST pull-down assay, RIP140 inhibited SRC1
binding to LXRa and vice versa (Figure 5F). Knockdown of
RIP140 caused a marked elevation in Srebf1c promoter activity
and, consequently, Srebf1 gene expression in the fasting state
(Figures 5G and 5H), but not in the fed state (Figure S5H), consis-
tent with a previous report (Berriel Diaz et al., 2008). Moreover,
RIP140 deficiency completely cancelled the effect of KLF15
knockdown on Srebf1c expression in the fasting state (Fig-Figure 4. Molecular Interaction between KLF15 and LXRa
(A and B) Coimmunoprecipitation of LXRawith KLF15. Nuclear extracts fromHEK
re-fed states were immunoprecipitated with anti-KLF15, anti-LXRa/b, or anti-FLA
(C) GST pull-down assays showing interactions between KLFs and LXRa. 35S
generated using an in vitro transcription/translation system were pulled down us
(D) Mammalian two-hybrid assay to examine interactions between KLFs and LXR
VP16-LXRa and GAL4-KLFs (n = 3 per group).
(E–G) Domain mapping of the interaction between KLF15 and LXRa.
(E) 35S-labeled recombinant KLF15 proteins generated using an in vitro transcripti
of GST-LXRa fusion proteins. RAD, repression and activation domain; ZF, zinc fi
(F) Functional domain analysis of KLF15 necessary for the suppression of LXR
plasmids, expression plasmids for Myc-tagged LXRa and RXRa, and plasmids f
(G) 35S-labeled recombinant full-length or deletion derivatives of KLF15 proteins
using a GST-LXRa fusion protein.
Results are presented as means ± SEM. *p < 0.05 and **p < 0.01 versus control
2380 Cell Reports 16, 2373–2386, August 30, 2016ure S5I), indicating that the effect of KLF15 on Srebf1c expres-
sion is completely dependent on RIP140.
From these results, we concluded that KLF15 suppresses
LXR by recruiting a RIP140 corepressor instead of an SRC1
coactivator.
KLF15 Ameliorates Hypertriglyceridemia
To explore the possible involvement of KLF15 in the pathogen-
esis of obesity-related metabolic disorders, we examined the
role of KLF15 in the hypertriglyceridemia observed in genetically
obese ob/ob mice. As shown in Figure 6A (and also in Figures
S6A and S6B), the expression level of KLF15 was significantly
lower in ob/ob mouse liver compared with control. Forced
restoration of KLF15 levels in ob/ob mice to wild-type levels
attenuated Srebf1 overexpression and led to an improvement
in hypertriglyceridemia (Figures 6B, 6C, and S6C–S6E) without
an elevation in blood glucose levels (Figure 6D).
As another animal model of hypertriglyceridemia, we
tested the effect of KLF15 activation on mice administered
T0901317, a synthetic LXR ligand. Administration of T0901317
induced hepatic SREBP-1c and caused hypertriglyceridemia.
When Ad-KLF15 adenovirus was transduced in the livers
of T0901317-treated mice, Srebf1 mRNA expression was
completely repressed to vehicle-treated control levels (Figures
6E, S6F, and S6G), resulting in a decrease in Fasn mRNA and
a concomitant decrease in plasma triglyceride levels with no ef-
fect on high-density lipoprotein (HDL) cholesterol levels (Figures
6F–6H). These results suggest that KLF15 is involved in the path-
ogenesis of obesity-related dyslipidemia and can be a therapeu-
tic target for treatment.
DISCUSSION
SREBP-1c is regulated at the transcription level depending upon
nutritional states, especially during cycles of fasting and refeed-
ing. Although the Srebf1c promoter is controlled by LXR, the pre-
cise molecular mechanism by which SREBP-1c expression is
nutritionally regulated was largely unknown. The current study
clearly demonstrates, using new nutrigenomic approaches,
that fasting-induced KLF15 forms a complex with LXR/RXR on
the Srebf1c promoter to repress the expression of SREBP-1c
and downstream lipogenic genes during the early and euglyce-
mic phases of fasting (Figure 7). Conversely, in the postprandial293 cells expressing these indicated proteins or frommouse livers in fasted and
G antibody. F, fasted; R, re-fed.
-labeled recombinant KLF15, KLF4, KLF1, KLF5, KLF9, and KLF10 proteins
ing GST-LXRa fusion proteins.
a in HEK293 cells cotransfected with Gal4-RE-Luc and expression vectors for
on/translation systemwere pulled down using full-length or deletion derivatives
nger.
a activity in cells. HEK293 cells were cotransfected with 250-Srebf1c-Luc
or KLF15, KLF15RAD, or KLF15ZFs (n = 3 per group).
generated using an in vitro transcription/translation system were pulled down
of each group. See also Figure S5.
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Figure 5. KLF15 Represses LXR by Recruiting the RIP140 Corepressor
(A) Recruitment of corepressors to LXRa by KLF15 as assessed using a mammalian two-hybrid system. HEK293 cells were cotransfected with Gal4-RE-Luc
plasmid and expression vectors for VP16-LXRa and GAL4-Corep-NID (Gal4-DBD fused to NID of RIP140, NcoR1 or SMRT) along with KLF15 expression plasmid
and incubated with media containing T0901317 (1 mM) (n = 3 per group).
(B) Coimmunoprecipitation of RIP140 with LXRa or KLF15.
(C) Recruitment of coactivator SRC1 to LXRa as assessed using a mammalian two-hybrid system (n = 3 per group).
(D) Coimmunoprecipitation of RIP140 and SRC1 using anti-LXR antibody. F, fasted; R, re-fed.
(E) Chromatin immunoprecipitation assay with anti-RIP140 and anti-SRC1 antibodies. PCRwas performed using primers for two LXREs and an NuRE-containing
region in the Srebf1c promoter.
(F) GST pull-down assay with GST-LXRa against RIP140 or SRC1. Unlabeled proteins were added as competitors.
(G and H) Knockdown of hepatic RIP140 using adenovirus-mediated RNAi (Ad-RIP140i).
(G) Images captured using IVIS and luciferase activities per transduced adenoviral DNA in the livers of fasted mice are shown (n = 5–12 per group). F, fasted; R,
re-fed.
(H) qRT PCR of gene expression in the fasted mouse livers from each group (n = 7–8 per group).
Results are presented as means ± SEM. *p < 0.05 and **p < 0.01 versus control of each group. See also Figure S5.state, KLF15 levels decrease and the suppressive complex
of KLF15-LXR/RXR-RIP140 was replaced by LXR/RXR-SRC1,
leading to activation of the Srebf1c promoter.
Before we began this study, it was well known that LXR can be
activated by ligands (Forman et al., 1997; Janowski et al., 1996;
Lehmann et al., 1997) and that diet-derived LXR ligandsmight be
the key inducer of SREBP-1 and lipogenic gene expression.
However, in our series of in vivo Ad-luc experiments elucidatingthe regulatory mechanism of LXR, we found out that the LXR-
binding cis elements alone were not sufficient for fasting-refeed-
ing regulation, although they exhibited a complete response to
an LXR ligand (Figure 1B). This finding clearly showed that the
fasting-refeeding regulation of SREBP-1c transcription is not
brought about by changes in LXR ligand concentration. In accor-
dance with this, LXR downstream genes such as ABCA1,
ABCG5, and ABCG8 in the liver show no response to refeedingCell Reports 16, 2373–2386, August 30, 2016 2381
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Figure 6. KLF15 Ameliorates Hypertrigly-
ceridemia
(A) Hepatic gene expression in 18-hr-fasted ob/ob
mice (n = 6–7 per group).
(B–D) KLF15 was elevated to wild-type levels in
ob/ob mice liver using Ad-KLF15. Hepatic gene
expression (B), plasma triglyceride levels (C), and
blood glucose levels (D) in 18-hr-fasted states are
shown (n = 5–6 per group).
(E–H) Effects of KLF15 activation on LXR-stimu-
lated hyperlipidemic mice. 1 day after Ad-KLF15
injection, mice were treated orally with 50 mg/kg
T0901317 once a day for 3 days in the ad lib state.
(E) Hepatic gene expression at 2 hr after the last
T0901317 treatment (n = 5 per group). (F–H)
Plasma lipid profiles at 5 hr after the last T0901317
treatment (n = 18–25 per group).
Results are presented as means ± SEM. *p < 0.05
and **p < 0.01 versus control of each group. See
also Figure S6.
2382 Cell Reports 16, 2373–2386, August 30, 2016
Fasted
Gluconeogenesis
FAS
Lipogenesis
Srebf1c-promoter
LXRE KLF site
KLF15
RIP140 SRC1
LXR KLF15
RIP140
Fed
(SREBP-1c target gene)
Srebf1c gene
FAS
(SREBP-1c target gene)
Srebf1c-promoter
Gluconeogenesis Lipogenesis
RIP140 SRC1
LXR
SRC1
LXRE KLF site Srebf1c gene
KLF15
Figure 7. KLF15 Enables Rapid Switching
between Lipogenesis and Gluconeogenesis
Schematic presentation of the molecular mecha-
nism by which KLF15 switches lipogenesis and
gluconeogenesis. See also Figure S7.(Oosterveer et al., 2008). It is also notable that another nuclear
receptor RAR besides LXR can function as a partner for KLF15
in this context (Figures S5A and S5B). From these lines of evi-
dence, we concluded that LXR ligands are not involved in the
fasting-refeeding response of lipogenic genes in the liver.
KLF15 is upregulated in fasting mouse liver and is known to
contribute to the regulation of hepatic gluconeogenesis (Gray
et al., 2007; Teshigawara et al., 2005). In light of the current
work, we propose that the regulation of lipogenesis and gluco-
neogenesis is coordinated by KLF15 and is reciprocally regu-
lated in response to nutritional conditions. Given that lipogenesis
is an adaptive process that facilitates survival during subsequent
starvation, it is conceivable that the key factor or factors
controlling lipogenesis are negatively regulated by these fast-
ing-induced factors.
In our previous publication, we reported that the PKA phos-
phorylation of LXR suppresses Srebf1c transcription by recruit-
ing a co-repressor NcoR1 (Yamamoto et al., 2007). To clarify
the relationship between KLF15-mediated and PKA-mediated
Srebf1c repression, we analyzed KLF15 knockout mice (Gray
et al., 2007). As shown in Figure 3G, KLF15 knockout mice ex-
hibited significantly higher Srebf1c promoter activity at an early
stage of fasting (6 hr of fasting). In contrast, after prolonged
fasting (24 hr of fasting), Srebf1c promoter activity in KLF15
knockout mice was suppressed to levels similar to those of
wild-type control mice. A series of experiments revealed that
the compensatory mechanism in KLF15 knockout mice that
finally suppressed Srebf1c expression to the same low levels
seen in wild-type after prolonged fasting was hypoglycemia-
induced PKA activation, which caused a suppression of LXR/
RXR transcriptional activity that was dependent on the on
NcoR1 co-repressor (Figures 3J, S4C–S4E, and S7A–S7E). Sup-
porting this finding, NcoR1 binding to the Srebf1c promoter as
assessed by ChIP assay was elevated in KLF15 knockout mice
(Figure S7C). Interestingly, PKA-mediated phosphorylation ofCell RepLXR did not affect RIP140 binding
to LXR (Figure S5E), demonstrating that
KLF15-RIP140-mediated repression is
independent of PKA-NcoR1-mediated
SREBP-1c repression.
This pathway from hypoglycemic
PKA stimulation to LXR suppression via
NcoR1 is usually activated in the pro-
longed fasting state, whereas KLF15-
mediated lipogenic suppression is seen
from the early and euglycemic periods.
It is conceivable that this earlier shut-
down of lipogenesis through the KLF15
pathway may help restart triglyceride
synthesis after refeeding sooner in wild-type mice than in KLF15 knockout mice (Figure S7F). Together
with the other important role of KLF15 in gluconeogenesis, the
KLF15-mediated pathway can be considered as an adaptive
and homeostatic mechanism of energy metabolism working
from the euglycemic phase of fasting before hypoglycemia and
PKA activation proceeds.
Previously, a detailed mutation analysis of SREBP-1c pro-
moter activity in primary hepatocytes was reported (Chen
et al., 2004), with no derepression of promoter activity around
the NuRE region. Whereas our analyses were based on intra-
organ assays using living animals, Chen et al. used cultured pri-
mary hepatocytes in their experiments, which might be the
cause of this discrepancy. In fact, the expression of KLF15
severely diminishes soon after primary hepatocytes are pre-
pared (data not shown), demonstrating the differences between
in vivo and in vitro settings. It is probable that our strategy of
starting from intra-organ assays to screen the cis elements
enabled us to successfully identify the KLF15-mediated
pathway.
Regarding the upstream regulatory mechanisms by which
KLF15 is induced during fasting, the possible involvement of
insulin was examined (Figure S7G). We found that STZ-induced
insulin deficiency partially increased KLF15 while it decreased
SREBP-1c, suggesting some molecular link between insulin
and KLF15. At the same time, it has been reported that hor-
mones other than insulin are involved in the regulation of
KLF15 expression (Teshigawara et al., 2005). These findings
are consistent with a previous report analyzing liver-specific
insulin receptor knockout (LIRKO) mice (Haas et al., 2012),
which revealed that although insulin signaling is necessary for
maximal induction, nutrients (either directly or indirectly, via
hormones other than insulin) are sufficient for the induction of
the SREBP-1c and lipogenic gene transcripts.
In the present study, we used our original library of tran-
scription factors, TFEL (N.Y. and Y.T, unpublished data), whichorts 16, 2373–2386, August 30, 2016 2383
covers nearly all the known transcription factors encoded by the
mouse genome, to identify the transcription factor binding to
NuRE in the presence of LXR/RXR. It is well known that binding
site prediction based on binding motif databases suffers from
high false-positive and false-negative rates in general (Kim and
Park, 2011). In particular, the sequence-based approach has
no power to predict transcription factor complexes formed by
protein-protein interactions.
Conversely, the search for protein-protein interactions among
transcription factors alone may not be sufficient to elucidate the
regulatory complexes in certain situations, including the present
case, because complexes like KLF15-LXR/RXR also depend on
cis elements (i.e., NuRE plus LXRE, in this case). This relatively
weak interaction supported by the DNA backbone enables
gene-specific regulations and may give more diversity to tran-
scriptional networks. Thus, our combinatorial strategy of search-
ing for a functional cis element and screening for the correspond-
ing transcription factor complex in a context-dependent manner
can be a very effective and powerful approach for exploring
sophisticated transcriptional networks in detail.
Synthetic LXR ligands have been expected to have atheropro-
tective effects through the promotion of reverse cholesterol
transport and inhibition of intestinal cholesterol absorption
(Joseph et al., 2002). However, the unfavorable side effect
of elevating plasma triglyceride levels has hampered the thera-
peutic application of LXR ligands. Our finding that KLF15
can specifically block the lipogenic effect of an LXR ligand pro-
vides therapeutic implications for the treatment of dyslipidemia,
including obesity-related diseases with SREBP-1c overexpres-
sion. Moreover, it is notable that KLF15 overexpression inmouse
liver, in contrast to primary cultured hepatocytes, whose expres-
sion levels of KLF15 and gluconeogenic genes are very low
(data not shown), does not lead to an excess gluconeogenesis
(Figures 6D, S3F, and S6D; Table S1). Thus, KLF15 overex-
pression can improve the plasma lipid profile without exacer-
bating hyperglycemia. Elucidating the upstream mechanisms
of KLF15 regulation will also be important from this therapeutic
point of view.
EXPERIMENTAL PROCEDURES
Animals
6- to 8-week-old ICRmale mice were purchased from Central Laboratories for
Experimental Animals (CLEA). 6- to 7-week-old ob/ob male mice were pur-
chased from SLC. KLF15 knockout mice were a gifted from Prof. M.K. Jain
and genotyped as previously described (Fisch et al., 2007), andwild-type litter-
mates were used as controls. All animals were maintained in a temperature-
controlled environment with a 12-hr light/dark cycle and given free access to
standard laboratory food and water. For the fasting group, animals were
starved 24 hr, and for the refeeding group, they were re-fed for 16 hr after a
24-hr starvation. For experiments using ob/ob mice, animals were starved
for 18 hr. For LXR ligand experiments of hepatic luciferase activity,
T0901317 was administered at a dose of 50 mg/kg after a 24-hr starvation
and analyzed 16 hr later. For experiments using insulin-depleted diabetic
mice, ICR male mice were administrated streptozotocin (two intraperitoneal
injections of 100 mg/kg body weight with a 1-day interval) as previously
described (Takeuchi et al., 2007). Mice were sacrificed in the early light
phase in a fasted, re-fed, or nonfasted (ad libitum) state. All animals studied
were anesthetized and euthanized according to a protocol approved by the
Tsukuba University Animal Care and Use Committee. All experiments were
repeated at least twice.2384 Cell Reports 16, 2373–2386, August 30, 2016Preparation of Recombinant Adenoviruses
Recombinant adenoviruses were constructed using the Gateway system
(Invitrogen). Details are provided in Supplemental Experimental Procedures.
In Vivo Imaging of Luciferase Activity
In vivo imaging was performed as described previously (Takeuchi et al., 2010).
3–6 days after adenovirus transduction, D-luciferin potassium salt (Wako)
was injected intraperitoneally (i.p.) into mice, and luminescence in the liver
was captured using an IVIS Imaging System (Xenogen). Relative photon emis-
sion over the liver regionwas quantified using LivingImage software (Xenogen).
When hepatic transduction efficiency was determined, quantification of
adenoviral DNA in the liver was performed using a previously described
qRT-PCR method (Takeuchi et al., 2007), and the result of quantification
was used to normalize the in vivo imaging of luciferase activity. Otherwise,
paired data from the same animal for the different nutritional conditions
(i.e., fasted or re-fed) were continuously obtained, and the ratio between the
two quantities was used to cancel the variations in hepatic transduction
efficiencies.
Genome-wide Transcription Factor Screening
TFEL clones (N.Y. and Y.T., unpublished data) were cotransfected with
the Srebf1c-(LXREx2+NuRE)-SV40p-Luc plasmid together with LXRa/RXRa
expression plasmids into HEK293 cells. The luciferase activity in transfec-
tants was then measured using a luminometer with a standard assay kit
(Promega).
Electrophoretic Mobility Shift Assay
EMSAs were performed as described previously (Amemiya-Kudo et al., 2000).
Details are provided in Supplemental Experimental Procedures.
Chromatin Immunoprecipitation Assay
Separation of hepatic nuclei frommouse liver andChIP assayswere performed
as described previously (Ide et al., 2004; Nakagawa et al., 2006). Chromatin
DNA was further purified with the Wizard DNA Clean-Up System (Promega)
and used as a template for PCR. Primers used to amplify the Srebf1c promoter
or SRE (sterol regulatory element) in Fasn promoter regions and reaction con-
ditions were described previously (Sekiya et al., 2007; Yamamoto et al., 2007).
As a positive control, 1% of the input genomic DNA was used.
RNA Isolation and Northern Blotting
Total RNA preparation and blot hybridization with cDNA probes were per-
formed as previously described (Takeuchi et al., 2010). Full-length cDNAs
were used for cDNA probes for mouse Klf15 and Klf4. The cDNA probe for
mouse Hpd was prepared by RT-PCR using mouse liver total RNA as a
template. The primers were as follows: 50-CATTTCCACTCGGTGACCT-30
and 50-TGTCTTGCTCCACCCATG-30. Rplp0 was used as a loading control.
Blots were exposed to a BAS imaging plate for the BAS2000 BIO Imaging
Analyzer (Fuji Photo Film).
qRT-PCR
Total RNA (2 mg) was reverse transcribed using the High Capacity cDNA
reverse transcription kit (Applied Biosystems). qRT-PCR was performed using
SYBR green dye (Kapa Biosystems) on a 7300 real-time PCR system (Applied
Biosystems). Primer sets are listed in Table S2.
Immunoblotting and Immunoprecipitation
Immunoblotting and immunoprecipitation were performed as described previ-
ously (Takeuchi et al., 2010; Yamamoto et al., 2007). Nuclear extract protein
from mouse liver and HEK293 cells was prepared as previously described
(Sheng et al., 1995; Yahagi et al., 2003, 2004).
Construction of the Tet-On System
A Tet-on system to rapidly activate KLF15 expression was constructed as
described previously (Urlinger et al., 2000). A modified rTetR fragment was
amplified by PCR from pUHD172-1 (Gossen et al., 1995). Tet response
element (TRE) was cloned from pSIREN-RetroQ-TetP (Clontech). Details are
provided in Supplemental Experimental Procedures.
GST Pull-Down Assay
GST and GST fusion proteins were prepared as described previously (Najima
et al., 2005) and dialyzed with dialysis buffer (50 mM Tris-HCl [pH 8.0], 50 mM
NaCl, 1 mM EDTA, and 1 mM DTT). [35S]Methionine-labeled proteins were
prepared using the TNT T7 quick-coupled transcription/translation system
(Promega). GST pull-down assays were performed as described previously
(Najima et al., 2005; Yamamoto et al., 2007).
Mammalian Two-Hybrid Assay
HEK293 cells were cotransfected with GAL4-RE-Luc plasmids and expression
plasmids for GAL4 fusion protein and VP16 fusion protein.
Statistical Analyses
Data are expressed as means ± SEM. Differences between two groups were
assessed using an unpaired two-tailed Student’s t test. Datasets involving
more than two groups were assessed by ANOVA with Statview Software
(BrainPower). Differences were considered statistically significant at p < 0.05
(*p < 0.05 and **p < 0.01).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.07.069.
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